ArticleClinical rheumatology2026
Longitudinal changes in renal function in rheumatoid arthritis patients treated with biologic agents: a retrospective cohort study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate longitudinal renal trajectories and predictors of kidney function in patients with rheumatoid arthritis (RA) receiving biologic therapies, using serial estimated glomerular filtration rate (eGFR) measurements during follow-up. As a secondary objective, renal outcomes were compared between anti-tumor necrosis factor (anti-TNF) agents and other biologic therapies.
methodThis single-center retrospective cohort study included 141 patients with RA fulfilling the 2010 ACR/EULAR classification criteria and receiving the same biologic therapy for at least one year. Renal parameters, including eGFR, creatinine, and urea, were assessed at baseline, every 6 months up to 24 months, and at final follow-up. Chronic kidney disease (CKD) was defined according to the 2024 KDIGO criteria. Propensity score matching (PSM) was performed to balance baseline characteristics between anti-TNF and non-TNF groups. Longitudinal renal changes were evaluated using linear mixed-effects models.
resultsBaseline CKD prevalence was 5.0%, and most patients had preserved renal function. During follow-up, significant longitudinal changes were observed in creatinine (p < 0.001) and eGFR (p = 0.002) in unadjusted analyses, whereas urea remained stable. However, in the adjusted linear mixed-effects model, the overall time effect on eGFR was not statistically significant (F = 1.080, p = 0.370). Type III tests demonstrated significant associations of treatment group (p = 0.032), RF group (p = 0.024), ILD (p = 0.008), disease duration (p = 0.028), and age (p < 0.001) with longitudinal eGFR variability. Patients receiving Anti-TNF therapy demonstrated higher eGFR values during follow-up (101.49 vs. 98.68 mL/min/1.73m
conclusionDifferences in longitudinal renal function were observed between treatment groups, but these findings should be interpreted cautiously because of residual confounding and baseline imbalances. Prospective studies are warranted to confirm these observations. Key Points • Renal function remained largely preserved in patients with rheumatoid arthritis receiving biologic therapies in real-world clinical practice. • Patients receiving anti-TNF therapy demonstrated higher eGFR values and distinct longitudinal renal trajectories compared with those receiving non-TNF biologics. • Age emerged as the strongest independent predictor of renal function, supporting the importance of long-term renal monitoring in RA patients receiving biologic therapy.
Indexed as
Identifiers
42665749What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.